🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Urinary Bladder Tumour

Trop2-targeted immunoPET Imaging of Solid Tumors NCT06851663Phase 2, Phase 31 site📍 Shanghai RenJi Hospital · Tests: [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4, [18F]F-RESCA-RT4 Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy NCT07662824NA1 site📍 Rochester Mayo Clinic · Tests: Educational Intervention, Interview, Flyte Medical Device Usage and Evaluation, Questionnaire Administration, Referral Preoperative Detection of Muscle Invasion in Bladder Cancer with Contrast-enhanced Ultrasonography NCT05204108n/a1 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University The Global En Bloc Resection of Bladder Tumour Registry NCT04934540n/a2 sites📍 Hong Kong📍 Hong Kong Chinese University of Hong Kong · Tests: En bloc resection of bladder tumour Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy NCT07144319n/a8 sites📍 Tampa📍 Ann Arbor📍 New Brunswick Photocure Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer NCT07474519Phase 41 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Accelerometry, BCG Solution, BCG Solution, BCG Solution, Electronic Health Record Review Urinary Microbiome Differences in Bladder Cancer, Benign Urinary Diseases and Healthy Counterparts in Adult Male Population NCT06992986n/a1 site📍 Rome Regina Elena Cancer Institute · Tests: Investigating differences in the bladder microbiome En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device NCT04235764n/a1 site📍 Bethesda National Cancer Institute (NCI) · Tests: modified resectoscope, TURBT Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection NCT06525571Phase 32 sites📍 Washington D.C.📍 Baltimore Johns Hopkins University · Tests: Cysview, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA NCT07413523NA1 site📍 Rozzano Istituto Clinico Humanitas · Tests: SBRT A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) NCT07222488Phase 1, Phase 217 sites📍 Bakersfield📍 New Brunswick📍 Myrtle Beach Merck Sharp & Dohme LLC · Tests: MK-3120 LaserEn: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors NCT04979156n/a1 site📍 Kansas City University of Kansas Medical Center · Tests: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors Chemoablation for Low-Grade Bladder Cancer NCT07019220Phase 21 site📍 Vienna Ekaterina Laukhtina · Tests: Gemcitabine Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer NCT06995677Phase 248 sites📍 Homewood📍 Little Rock📍 Murrieta Tyra Biosciences, Inc · Tests: TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose 70 mg Validity of Parametric MRI Using VIRADS NCT05783271NA1 site📍 Asyut Assiut University · Tests: Gadolinium Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer NCT07646145Phase 21 site📍 Taiyuan Shanxi Province Cancer Hospital · Tests: Disitamab Vedotin, Mitomycin C (MMC) Sacituzumab Govitecan Plus EV in Metastatic UC NCT04724018Phase 1, Phase 21 site📍 Boston Dana-Farber Cancer Institute · Tests: Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma NCT06364956Phase 1, Phase 28 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: Tislelizumab combined with two predefined dose groups of palbociclib, RP2D dose Of Tislelizumab combined with palbocicl… A Feasibility Randomized Trial Evaluating Early vs Late Stent Removal Following Radical Cystectomy and Ileal Conduit Formation for Bladder Cancer NCT06595446NA1 site📍 London Western University, Canada · Tests: Early Stent removal, Late Stent removal Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed? NCT07037589n/a1 site📍 Uddevalla Vastra Gotaland Region · Tests: investigation setting (cystoscopy + CTU + cytology), Cystoscopy - CTU - cytology (if needed) Analysis of Urinary Methylation Patterns Via Liquid Biopsy as an Early Diagnosis Tool NCT06878027n/a1 site📍 Rome Regina Elena Cancer Institute The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy NCT06388720Phase 21 site📍 Goyang-si National Cancer Center, Korea · Tests: Mitomycin-C, gemcitabine A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer NCT06892860Phase 23 sites📍 Paris📍 Madrid📍 London Queen Mary University of London · Tests: Avelumab The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial) NCT05726786Phase 34 sites📍 Lausanne📍 Bern📍 Geneva Centre Hospitalier Universitaire Vaudois · Tests: Immunonutrition A First in Human Study of PLT012 in Participants With Solid Tumor Cancers NCT07337525Phase 14 sites📍 Los Angeles📍 Dallas📍 Houston Pilatus Biosciences Inc · Tests: PLT012 Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer NCT07187635NA7 sites📍 Nanchang📍 Guangzhou📍 Xingtai Tianjin Medical University Second Hospital · Tests: Second Transurethral Resection of Bladder Tumor (re-TURBT), utDNA Testing (Urine Tumor DNA Detection) The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection NCT06287541NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Urine biomarker -Guided without reTURBT Comprehensive Geriatric Assessment for Perioperative Optimization in Cystectomy NCT05679557NA1 site📍 Odense Aarhus University Hospital · Tests: Perioperative geriatric assessment and intervention Sacral Neuromodulation for Male Overactive Bladder (MOAB) NCT06511141NA23 sites📍 Birmingham📍 Fairhope📍 Scottsdale Axonics, Inc. · Tests: Axonics SNM System
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy